安科生物(300009.SZ):參股公司博生吉增資擴股引入中金等5家投資者
格隆匯1月6日丨安科生物(300009.SZ)公佈,博生吉醫藥科技(蘇州)有限公司(簡稱“博生吉公司”)系公司的參股公司,公司持有其19.55%股權。近日,博生吉公司為解決業務發展所需資金,擬以增資擴股方式引入新投資方。
中金啟德(廈門)創新生物醫藥股權投資基金合夥企業(有限合夥)、南京華泰國信醫療投資合夥企業(有限合夥)、南京道興投資管理中心(普通合夥、蘇州磐毅博生創業投資合夥企業(有限合夥)、淄博瑞桐創業投資合夥企業(有限合夥)擬以現金方式對博生吉公司進行增資,公司及博生吉公司其他原股東均放棄該次增資優先認購權。
該次增資後,博生吉公司註冊資本由人民幣533.1299萬元增加至人民幣618.4307萬元,公司持有博生吉公司的股權比例由19.55%降至16.85%,博生吉公司仍為公司參股公司。
博生吉公司是一家技術驅動、科創屬性極強的CAR-T細胞藥物研發企業,目前博生吉公司產品正處於研發階段,因此,公司放棄該次增資優先認購權是基於公司經營方針及適當控制風險等因素作出的審慎決策。該次放棄權利不改變公司合併報表範圍,也不會對公司的財務狀況、經營成果、未來主營業務和持續經營能力產生不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.